Header

UZH-Logo

Maintenance Infos

Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study


Boubaker, K; Flepp, M; Sudre, P; Furrer, H; Haensel, A; Hirschel, B; Boggian, K; Chave, J‐P; Bernasconi, E; Egger, M; Opravil, M; Rickenbach, M; Francioli, P; Telenti, A (2001). Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 33(11):1931-1937.

Abstract

The prevalence, clinical presentation, and risk factors for hyperlactatemia among patients receiving antiretroviral therapy was determined during a 1-month period for patients in the Swiss HIV Cohort Study. Overall, 73 (8.3%) of 880 patients presented an increase in serum lactate of >1.1 times the upper normal limit (UNL). For 9 patients (1%), lactate elevation was moderate or severe (>2.2 times the UNL). Patients who presented with hyperlactatemia were more likely to be receiving stavudine with or without didanosine (odds ratio, 2.7; 95% confidence interval, 1.5-4.8), as compared with patients who received zidovudine-based regimens. The risk increased with increasing time receiving stavudine with or without didanosine. The association between hyperlactatemia and stavudine with or without didanosine was not biased by these medications being more recently available and, therefore, being given preferentially to patients who had prolonged use of nucleoside analog reverse-transcriptase inhibitors. Hyperlactatemia was associated with lipoatrophy, hyperlipidemia, and hyperglycemia. Age, sex, or stage of infection with human immunodeficiency virus were not predictive of hyperlactatemia. Determination of lactate levels may prove useful in the screening for mitochondrial toxicity

Abstract

The prevalence, clinical presentation, and risk factors for hyperlactatemia among patients receiving antiretroviral therapy was determined during a 1-month period for patients in the Swiss HIV Cohort Study. Overall, 73 (8.3%) of 880 patients presented an increase in serum lactate of >1.1 times the upper normal limit (UNL). For 9 patients (1%), lactate elevation was moderate or severe (>2.2 times the UNL). Patients who presented with hyperlactatemia were more likely to be receiving stavudine with or without didanosine (odds ratio, 2.7; 95% confidence interval, 1.5-4.8), as compared with patients who received zidovudine-based regimens. The risk increased with increasing time receiving stavudine with or without didanosine. The association between hyperlactatemia and stavudine with or without didanosine was not biased by these medications being more recently available and, therefore, being given preferentially to patients who had prolonged use of nucleoside analog reverse-transcriptase inhibitors. Hyperlactatemia was associated with lipoatrophy, hyperlipidemia, and hyperglycemia. Age, sex, or stage of infection with human immunodeficiency virus were not predictive of hyperlactatemia. Determination of lactate levels may prove useful in the screening for mitochondrial toxicity

Statistics

Citations

Dimensions.ai Metrics
153 citations in Web of Science®
196 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

18 downloads since deposited on 25 Sep 2018
18 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 December 2001
Deposited On:25 Sep 2018 13:03
Last Modified:24 Sep 2019 23:40
Publisher:Oxford University Press
ISSN:1058-4838
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1086/324353
Related URLs:https://www.swissbib.ch/Search/Results?lookfor=nationallicenceoxford101086324353 (Library Catalogue)

Download

Download PDF  'Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 100kB
View at publisher